A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

A Real-world Study of the Efficacy and Safety of Obinutuzumab-based Therapy for Previously Untreated Follicular Lymphoma

This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma

This study aims to observe and explore the efficacy and safety of obinutuzumab-based therapy for previously untreated follicular lymphoma. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors.

Inclusion Criteria:

• Pathologically confirmed CD20 positive follicular lymphoma grade 1, 2, or 3A based on 2016 WHO classification
• Treatment naive
• Age ≥ 18 years
• Indications for treatment confirmed
• Must has measurable lesion in CT or PET-CT prior to treatment
• Considered suitable for GR, GB or GCHOP regimens
• Informed consented

Exclusion Criteria:

• Transformed follicular lymphoma or 3B follicular lymphoma;
• HBsAg positive and / or HBcAb positive with HBV DNA titer; HCV antibody positive with HCV-RNA; or HIV positive
• Central nervous system or meninges involved
• Any drug contraindication in the treatment plan
• Patients judged by other researchers to be unsuitable for inclusion in the study